Medtronic reported adjusted earnings of $1.55 per share, slightly above estimates, and revenue rose 9.9% year-over-year to $9.81 billion, driven by strong cardiovascular segment growth. BTIG upgraded Medtronic from Neutral to Buy, citing accelerating organic growth and undervaluation compared to peers. Leerink Partners lowered its price target to $104 but maintained an Outperform rating, highlighting Medtronic's strong commercial execution and growth potential. Shares rose 4.3% following the earnings beat and positive analyst commentary.

More News (MDT)

Healthcare services market to reach $20.10T by 2035, driven by digital health and AI adoption.

The global healthcare services market, valued at $8.62 trillion in 2025, is projected to grow to $20.10 trillion by 2035 at a CAGR of 8.87%. Growth is driven by rising chronic diseases, aging populations, and increased demand for personalized and acc...

Market News

Bullish

3 days ago